BALAXI PHARMACEUTICALS LIMITED (BALAXI) - Net Assets
Based on the latest financial reports, BALAXI PHARMACEUTICALS LIMITED (BALAXI) has net assets worth Rs2.38 Billion INR (≈ $25.74 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs3.22 Billion ≈ $34.87 Million USD) and total liabilities (Rs844.30 Million ≈ $9.13 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check BALAXI tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs2.38 Billion |
| % of Total Assets | 73.82% |
| Annual Growth Rate | 61.21% |
| 5-Year Change | 256.63% |
| 10-Year Change | 735869.85% |
| Growth Volatility | 2027.58 |
BALAXI PHARMACEUTICALS LIMITED - Net Assets Trend (2013–2025)
This chart illustrates how BALAXI PHARMACEUTICALS LIMITED's net assets have evolved over time, based on quarterly financial data. See BALAXI PHARMACEUTICALS LIMITED liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for BALAXI PHARMACEUTICALS LIMITED (2013–2025)
The table below shows the annual net assets of BALAXI PHARMACEUTICALS LIMITED from 2013 to 2025. For live valuation and market cap data, see BALAXI market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | Rs2.32 Billion ≈ $25.06 Million |
+15.08% |
| 2024-03-31 | Rs2.01 Billion ≈ $21.78 Million |
+10.11% |
| 2023-03-31 | Rs1.83 Billion ≈ $19.78 Million |
+61.61% |
| 2022-03-31 | Rs1.13 Billion ≈ $12.24 Million |
+74.15% |
| 2021-03-31 | Rs649.80 Million ≈ $7.03 Million |
+134.20% |
| 2020-03-31 | Rs277.46 Million ≈ $3.00 Million |
+688.12% |
| 2019-03-31 | Rs35.21 Million ≈ $380.73K |
+126.46% |
| 2018-03-31 | Rs15.55 Million ≈ $168.13K |
-34.10% |
| 2017-03-31 | Rs23.59 Million ≈ $255.13K |
+7392.46% |
| 2016-03-31 | Rs314.87K ≈ $3.41K |
-2.35% |
| 2015-03-31 | Rs322.45K ≈ $3.49K |
-95.86% |
| 2014-03-31 | Rs7.80 Million ≈ $84.33K |
+3.67% |
| 2013-03-31 | Rs7.52 Million ≈ $81.34K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to BALAXI PHARMACEUTICALS LIMITED's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 605186.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Rs1.63 Billion | 70.54% |
| Common Stock | Rs110.42 Million | 4.76% |
| Other Components | Rs572.23 Million | 24.69% |
| Total Equity | Rs2.32 Billion | 100.00% |
BALAXI PHARMACEUTICALS LIMITED Competitors by Market Cap
The table below lists competitors of BALAXI PHARMACEUTICALS LIMITED ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Intrusion Inc
NASDAQ:INTZ
|
$14.14 Million |
|
K Wave Media Ltd.
NASDAQ:KWM
|
$14.14 Million |
|
Wanted Lab Inc.
KQ:376980
|
$14.14 Million |
|
NSX Ltd
AU:NSX
|
$14.16 Million |
|
NetX Holdings Bhd
KLSE:0020
|
$14.13 Million |
|
Klimator AB
ST:KLIMAT
|
$14.11 Million |
|
MSCM Holdings Bhd
KLSE:0041
|
$14.11 Million |
|
Euromedis Groupe SA
PA:ALEMG
|
$14.11 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BALAXI PHARMACEUTICALS LIMITED's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,013,639,000 to 2,317,363,000, a change of 303,724,000 (15.1%).
- Net income of 250,702,000 contributed positively to equity growth.
- Share repurchases of 27,045,000 reduced equity.
- New share issuances of 27,045,000 increased equity.
- Other comprehensive income decreased equity by 37,728,000.
- Other factors increased equity by 90,750,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs250.70 Million | +10.82% |
| Share Repurchases | Rs27.05 Million | -1.17% |
| Share Issuances | Rs27.05 Million | +1.17% |
| Other Comprehensive Income | Rs-37.73 Million | -1.63% |
| Other Changes | Rs90.75 Million | +3.92% |
| Total Change | Rs- | 15.08% |
Book Value vs Market Value Analysis
This analysis compares BALAXI PHARMACEUTICALS LIMITED's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.56x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 165.78x to 0.56x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-03-31 | Rs0.14 | Rs23.67 | x |
| 2014-03-31 | Rs0.15 | Rs23.67 | x |
| 2015-03-31 | Rs0.01 | Rs23.67 | x |
| 2016-03-31 | Rs0.01 | Rs23.67 | x |
| 2017-03-31 | Rs7.76 | Rs23.67 | x |
| 2018-03-31 | Rs0.30 | Rs23.67 | x |
| 2019-03-31 | Rs0.67 | Rs23.67 | x |
| 2020-03-31 | Rs5.27 | Rs23.67 | x |
| 2021-03-31 | Rs12.34 | Rs23.67 | x |
| 2022-03-31 | Rs21.49 | Rs23.67 | x |
| 2023-03-31 | Rs34.72 | Rs23.67 | x |
| 2024-03-31 | Rs38.23 | Rs23.67 | x |
| 2025-03-31 | Rs41.92 | Rs23.67 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BALAXI PHARMACEUTICALS LIMITED utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.82%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.68%
- • Asset Turnover: 0.93x
- • Equity Multiplier: 1.34x
- Recent ROE (10.82%) is below the historical average (16.34%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 5.88% | 51.33% | 0.07x | 1.65x | Rs-309.88K |
| 2014 | 14.05% | 56.78% | 0.16x | 1.54x | Rs315.65K |
| 2015 | 317.43% | 82.71% | 3.36x | 1.14x | Rs991.30K |
| 2016 | -255.26% | -169.17% | 1.33x | 1.13x | Rs-835.21K |
| 2017 | -33.47% | 0.00% | -0.24x | 1.09x | Rs-10.25 Million |
| 2018 | -49.65% | 0.00% | 0.00x | 1.08x | Rs-9.27 Million |
| 2019 | 55.84% | 14.46% | 2.23x | 1.73x | Rs16.14 Million |
| 2020 | 22.00% | 13.38% | 1.27x | 1.30x | Rs33.29 Million |
| 2021 | 58.69% | 16.49% | 2.32x | 1.53x | Rs316.39 Million |
| 2022 | 42.11% | 17.06% | 1.58x | 1.56x | Rs363.41 Million |
| 2023 | 25.13% | 13.66% | 1.40x | 1.31x | Rs276.75 Million |
| 2024 | -1.19% | -0.99% | 0.93x | 1.28x | Rs-225.23 Million |
| 2025 | 10.82% | 8.68% | 0.93x | 1.34x | Rs18.97 Million |
Industry Comparison
This section compares BALAXI PHARMACEUTICALS LIMITED's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $41,118,163,484
- Average return on equity (ROE) among peers: 13.86%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BALAXI PHARMACEUTICALS LIMITED (BALAXI) | Rs2.38 Billion | 5.88% | 0.35x | $14.13 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $366.97 Million | 3.51% | 2.41x | $25.11 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.23 Billion | 12.93% | 2.27x | $365.36 Million |
| Aarti Pharmalabs Limited (AARTIPHARM) | $2.31 Million | -8.08% | 0.08x | $645.54 Million |
| Abbott India Limited (ABBOTINDIA) | $2.31 Billion | 29.62% | 0.43x | $6.01 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $32.64 Billion | 21.83% | 0.24x | $4.15 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.23 Billion | 13.11% | 3.52x | $996.26 Million |
| Alkem Laboratories Limited (ALKEM) | $75.58 Billion | 20.97% | 0.52x | $6.95 Billion |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $1.09 Billion | 18.92% | 0.29x | $170.62 Million |
| Alembic Pharmaceuticals Limited (APLLTD) | $22.20 Billion | 18.58% | 0.77x | $1.59 Billion |
| Aurobindo Pharma Limited (AUROPHARMA) | $268.52 Billion | 7.18% | 0.49x | $8.98 Billion |
About BALAXI PHARMACEUTICALS LIMITED
Balaxi Pharmaceuticals Limited engages in the international wholesale distribution of pharmaceuticals, builders hardware, and FMCG products in India, Africa, and Latin America. The company offers pharmaceutical products across various therapeutic areas, including antibiotics, analgesic, anti-malaria, and others. It also provides biscuits and toothpaste. The company was formerly known as Balaxi Ve… Read more